b Hopital Lyon Sud

Hôpital-Camfrout, France

b Hopital Lyon Sud

Hôpital-Camfrout, France

Time filter

Source Type

PubMed | g Hopital Saint Antoine, Amgen, e RJM Group, b Hopital Lyon Sud and 2 more.
Type: Journal Article | Journal: Journal of medical economics | Year: 2016

Philadelphia chromosome negative [Ph(-)] relapsed or refractory (R/R) B-precursor acute lymphoblastic leukemia (ALL) is an extremely rare condition requiring intensive treatment. This retrospective chart review aimed to quantify hospitalizations and reimbursement in this patient population in France.Patients aged 18 years and with at least one hospitalization for Ph(-) R/R B-precursor ALL were included in the study. They were relapsed with first remission lasting <12 months, relapsed after first salvage therapy, relapsed any time after hematopoietic stem cell transplant (HSCT), or were refractory to initial or salvage therapy. Data were collected from the index date (first diagnosis of R/R ALL) until death or loss to follow-up. The chemotherapy period was defined as the first chemotherapy date after the index date to the earliest of death, loss to follow-up, last chemotherapy dose plus 30 days, or initiation of HSCT. The primary outcome was the percentage of time hospitalized during the chemotherapy period.Thirty-three patients were included, with a mean age of 49 years. The mean proportion of time spent in the hospital during the chemotherapy period was 46% (95% CI =34-57%). Patients had a mean of 2.2 (SD =1.5) inpatient hospitalizations and the mean length of stay per hospitalization was 16.8 (SD =14.8) days. During the chemotherapy period, the mean amount reimbursed per hospitalization was 31 067 (SD = 4850) and the total hospitalization reimbursement per patient was 68 344. From the index date to death, excluding HSCT, the total reimbursement per patient was 108 873.The sample size was small, although this was expected given the rarity of the patient population.Adults with Ph(-) R/R B-precursor ALL had repeated and prolonged hospitalizations during salvage chemotherapy. Approximately half the follow-up period was spent in the hospital, and this time was associated with high economic burden in France.

Loading b Hopital Lyon Sud collaborators
Loading b Hopital Lyon Sud collaborators